<SEC-DOCUMENT>0001140361-20-027746.txt : 20201209
<SEC-HEADER>0001140361-20-027746.hdr.sgml : 20201209
<ACCEPTANCE-DATETIME>20201209061337
ACCESSION NUMBER:		0001140361-20-027746
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20201208
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201209
DATE AS OF CHANGE:		20201209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IONIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000874015
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330336973
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19125
		FILM NUMBER:		201376848

	BUSINESS ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010
		BUSINESS PHONE:		7609319200

	MAIL ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ISIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10017778_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ions="http://ionispharma.com/20201208" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: SUMMIT
         Document created using EDGARfilings PROfile 7.3.0.0
         Copyright 1995 - 2020 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_e9b190f64daa4bd3a2cbdd79bb268c08" contextRef="c20201208to20201208" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_305aa79557bf4bcc9e848cf8185df3b9" contextRef="c20201208to20201208">0000874015</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ions-20201208.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20201208to20201208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-08</xbrli:startDate><xbrli:endDate>2020-12-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C.&#160; 20549</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_a7f96fdf1edf447c98a518c5ae53250f" contextRef="c20201208to20201208">8-K</ix:nonNumeric></div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SECURITIES EXCHANGE ACT OF 1934</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of report (Date of earliest event reported):&#160; <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_f6cac525beb94deaa225975cf5769101" contextRef="c20201208to20201208" format="ixt:datemonthdayyearen">December 8, 2020</ix:nonNumeric></div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_207bac9ad4364357a0d1b8abb8a4e692" contextRef="c20201208to20201208">IONIS PHARMACEUTICALS, INC.</ix:nonNumeric><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Exact Name of Registrant as Specified in Charter)</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_4667772ae2e242a0bbca79d45cb90f4d" contextRef="c20201208to20201208" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" id="zfaf1353281d0436a813794a2115a7164" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_df9bdd1e42874b4d99bbb92356e4fece" contextRef="c20201208to20201208">000-19125</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_1be3552bc8104f51a8ef2da949aefc70" contextRef="c20201208to20201208">33-0336973</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center;">(Commission File No.)</div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center;">(IRS Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_2e5646431e7f446fb8216bddce6d825a" contextRef="c20201208to20201208">2855 Gazelle Court</ix:nonNumeric><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_ea743fda4de54a79b25f357bf3bd6e2a" contextRef="c20201208to20201208">Carlsbad</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_2d4c672aee474a3288cf04bf38d8785e" contextRef="c20201208to20201208">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_d88d9b84bbc047ed89e862cd070ef3a8" contextRef="c20201208to20201208">92010</ix:nonNumeric></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Address of Principal Executive Offices and Zip Code)</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_6c35838d472f43039b813e8e84d66740" contextRef="c20201208to20201208">760</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_decde9ed4f254df68be3bf309e2fcca5" contextRef="c20201208to20201208">931-9200</ix:nonNumeric></span></div>

        <div style="font-size: 10pt; font-family: 'Times New Roman';"><br />
        </div>

      </div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
        provisions:</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br />
        </span></div>

      <table cellspacing="0" cellpadding="0" id="z2fc9ca6c4d684209ab5a0f4908705d48" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_fbb4a19851174eeb84218efc2398e9db" contextRef="c20201208to20201208" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
              <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br />
        </span></div>

      <table cellspacing="0" cellpadding="0" id="zbee8c7c715ae42f38e58dae189ff87b9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_99f2a24f1234474a95c9d6c2f4d4ea78" contextRef="c20201208to20201208" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
              <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br />
        </span></div>

      <table cellspacing="0" cellpadding="0" id="zf53356cea593480db4ff9219a91ac3d8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_d52bdedea7ed42b3bb096080bb127adc" contextRef="c20201208to20201208" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
              <div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br />
        </span></div>

      <table cellspacing="0" cellpadding="0" id="zdec11e09b7bd4443a7081d4543c67bb8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_869c99fac6ee4e31a00572d792ade533" contextRef="c20201208to20201208" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
              <div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" id="z1188277c386e4062b943a463efe26908" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; color: rgb(0, 0, 0);">Title of each class</div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; color: rgb(0, 0, 0);">Trading symbol</div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; color: rgb(0, 0, 0);">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_bf46a798d2ac49fda3aafda61e189257" contextRef="c20201208to20201208">Common Stock, $.001 Par Value</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_8a6d249a77b0408cb0d83fe54671b9dd" contextRef="c20201208to20201208">&#8220;IONS&#8221;</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_07257a0299a84cd2bbfb1bb30ec081b7" contextRef="c20201208to20201208" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or
        Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>

      <div>
        <div style="text-align: right;">Emerging growth company <a id="z_Hlk11148519"></a> &#160; &#160; <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_f99dd419f2f444dbb89d066ffc3395be" contextRef="c20201208to20201208" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

      </div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; <span style="color: rgb(0, 0, 0);">&#9744;</span></div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /> </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <table cellspacing="0" cellpadding="0" id="za4351ce5bd4241d1aff0f2d008deecca" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 8.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="font-weight: bold;">Other Events.</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On December 8, 2020, Ionis Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing highlights of its Investor Day webcast conducted on December 7,
        2020.</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A copy of the release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <table cellspacing="0" cellpadding="0" id="z875931499057456084efa2a2e1865c43" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="font-weight: bold;">Exhibits.</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits.</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" id="z3f594047fef44c3ca040616c80af8d87" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 10%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">Exhibit No.</span></div>
            </td>

    <td style="width: 90%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; font-weight: bold;"><span style="text-decoration: underline;">Description</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" rowspan="1">&#160;</td>

    <td style="width: 90%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center;"><a href="brhc10017778_ex99-1.htm">99.1</a></div>
            </td>

    <td style="width: 90%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left;">Press Release dated December 8, 2020.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" rowspan="1">&#160;</td>

    <td style="width: 90%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" rowspan="1">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">104</div>
            </td>

    <td style="width: 90%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" rowspan="1">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
            </td>

  </tr>


</table>
      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br />
        </span></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">SIGNATURE</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
        behalf by the undersigned, thereunto duly authorized.</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" id="z2ccacca4ae4b4b088e8c748d4d1b75c8" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" colspan="2">
              <div style="text-align: justify; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 45%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman'; padding-bottom: 2px;">
              <div style="text-align: justify;">Dated:&#160; December 8, 2020</div>
            </td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman'; padding-bottom: 2px;">
              <div style="text-align: justify;">By:</div>
            </td>

    <td style="width: 45%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman'; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">/s/ Patrick R. O&#8217;Neil</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 45%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: justify; font-variant: small-caps; font-weight: bold;">Patrick R. O&#8217;Neil</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 45%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: justify;">Executive Vice President, Legal, General Counsel and Chief Compliance Officer</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br />
      </div>

    </div>

    <div> <span style="font-size: 10pt; font-family: 'Times New Roman';"><br />
      </span></div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /> </div>

  </div>

  <div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10017778_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: SUMMIT
         Document created using EDGARfilings PROfile 7.3.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"> <font style="font-weight: bold;">Exhibit 99.1</font><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: left;"><img width="202" height="67" src="image0.jpg"></div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis highlights achievements, commercial strategy and technology advancements at Investor Day</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zd6941d8c11a045668759e9b3942d42f8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Prioritizing and preparing its growing Ionis-owned pipeline for commercialization</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zb9cbf55f2f8143358488b3ac2b613993" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Potential to launch 6+ new products in next five years</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zd98eb08a9a80454a9c02d08378788287" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Positioned for a strong 2021 and beyond</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">CARLSBAD, Calif., Dec. 8, 2020</font> &#8211; At its Investor Day yesterday, Ionis
        Pharmaceuticals, Inc. (NASDAQ: IONS) highlighted the company&#8217;s significant achievements in 2020 and outlined its strategy to realize the substantial opportunity of its pipeline.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Hlk58308891"></a>Ionis has been preparing and prioritizing its growing wholly owned pipeline for commercialization in line with its commercial strategy. The
        company&#8217;s commercial priorities are three-fold: (1) Initially focusing its commercial efforts on rare diseases within its prolific neurology and cardiology franchises (2) pioneer new markets where there are no available treatments (3) create new
        standards of care where there has been a lack of innovation to optimize patient care.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Delivering on these three priorities will have meaningful impact to patients, their families, and healthcare providers all while reducing the burden on healthcare systems
        and driving value for all Ionis&#8217; stakeholders including patients and shareholders.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ionis also has plans to expand opportunistically to new products in additional treatment areas such as hematology, endocrinology and pulmonology.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ionis projects having the opportunity to launch six or more new products through 2026, with each being ready for launch in a close window, ranging from 18 to 24 months
        between each new product launch. The expectation is that the implementation of this strategy will drive double-digit revenue growth and substantial earnings growth.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Brett P. Monia, Ph.D., chief executive officer at Ionis, said, &#8220;In 2020, we pursued an aggressive agenda focused on building our commercial plans and capabilities,
        progressing the Ionis-owned pipeline, advancing our technology and growing our leadership position in RNA-targeted therapeutics. We are pleased to say that we delivered against all these objectives. We invested in building our commercial plans and
        capabilities and began implementation. These actions were accelerated through the acquisition of our commercial affiliate Akcea. We have also progressed and substantially expanded the Ionis-owned pipeline. In addition, we have six Phase 3 trials
        underway, initiated 13 Phase 2 trials, achieved multiple, positive clinical proof-of-concept readouts, and advanced new delivery platforms.&#8221;</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Dr. Monia continued, &#8220;For years we have been recognized for our excellence in research, early drug development and scientific innovation. We will now add to this by
        building a strong and efficient commercial organization of equal excellence. All of which will provide substantial benefit to patients and shareholders for years to come.&#8221;</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Highlights of Investor Day</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z1948a166bfd3465792aaa5b3c6dd52fc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis estimates the total market opportunity for the indications targeted by its pipeline is well in excess of $15 billion, with a significant portion from its
                wholly owned medicines.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zf1992074647a4c6b8c444de030aed94c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Ionis&#8217; cardiovascular franchise includes many potential first-in-class and/or best-in-class
                  medicines targeting a full spectrum of cardiovascular disease risk factors</font>. <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">The company is positioned to potentially launch multiple Ionis-owned
                  cardiovascular medicines through 2026, including:</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z386ded79d3e64694aa6ce19fef2f3b3c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">AKCEA-APOCIII-L</font><sub style="font-weight: bold; vertical-align: bottom; line-height: 1; font-size: smaller;">Rx</sub>: One product with the potential for
                addressing multiple indications targeting elevated triglycerides and the opportunity to set a new standard of care for triglyceride management</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z7ed7c80ab96447f7ac09063f52eb2526" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">91% of patients achieved normal serum triglycerides levels with favorable safety and tolerability in Phase 2</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zec5142be2b8a4168ab499c946f0a410e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><u><font style="font-size: 10pt; font-family: 'Times New Roman';">As announced</font> </u>on Dec. 1, 2020, a Phase 3 study in patients with familial chylomicronemia syndrome (FCS)
                is now underway</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z19453ac300514b5c94c7488c8fe80924" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Evaluating additional indications with plans to initiate an additional Phase 3 study in 2021</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z14021ceebc8946cab860d47052a73140" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">AKCEA-TTR-L</font><sub style="font-weight: bold; vertical-align: bottom; line-height: 1; font-size: smaller;">Rx</sub>: Opportunity to significantly expand
                ATTR franchise</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z3dd2424b34c445a1aafc8b0d550a308c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Robust target reductions of more than 90% and favorable safety and tolerability demonstrated in Phase 1</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z2c09b35be9d9470b884a30451732d662" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Flexibility of at-home monthly self-administration</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z1d1fc436d08a4db8881754476a7e861b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Two Phase 3 studies underway &#8211; CARDIO-TTRransform for patients with hereditary or wild type TTR cardiomyopathy and NEURO-TTRansform for patients with hereditary TTR polyneuropathy.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="za738eda8c6884b7189415723e9c8571f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">IONIS-AGT-L</font><sub style="font-weight: bold; vertical-align: bottom; line-height: 1; font-size: smaller;">Rx</sub><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">:</font> Large unmet need in patients with treatment-resistant hypertension (RHTN)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zb7a00521763b45c88b654984146bc7c0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Two Phase 2 clinical studies: Patients with mild HTN and patients with uncontrolled HTN who are on two (65%) or three (35%) antihypertensive medications</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z2effbc6eb27c4744830c9df2abfe7018" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Positive Phase 2 study in patients in uncontrolled HTN: patients achieved mean reductions of 12 mmHg and 6 mmHg in systolic and diastolic blood pressure from their own baseline,
                respectively, after eight weeks of once-weekly 80 mg IONIS-AGT-L<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">Rx</sub></div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z9413986817564d4c84ff51c2999ecba9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">IONIS-AGT-L<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">Rx</sub> has demonstrated a favorable safety and tolerability profile in clinical trials to date</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z188a80cf7e7147e79fb877c8c73396f3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">More detailed results to be presented at an upcoming medical conference</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z10b3678e79c74b7c8fcb50db141acfaf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis&#8217; neurology franchise has the potential to establish the standard of care for millions of patients and generate substantial value as it advances its
                first-in-class medicines to the market. The neurological disease market is a nascent market poised for substantial growth. Ionis believes it can be the catalyst for this growth as it is positioned to launch multiple Ionis-owned medicines
                through 2026, including:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z3ece765a7c044777b62369e634c2aba5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">ION363</font>: First medicine in development to specifically target FUS-ALS, a rare, rapidly
                progressing form of ALS</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z6e0aa62f793d40aab17974c41efe6138" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Pivotal study on track for initiation in 2021</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z8875b1204b8743db8512e3b452430780" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Potential for a rapid path to the market</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z1f54909af10042639a548b89e8dd4581" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">ION716</font>: Potential to be first approved treatment for prion diseases</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zdc92e402638e424f918c951ff1907ceb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Designed to reduce production of prion protein, root cause of prion disease</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zce5ca96932734887830e7b32ffe0f1b1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Pursuing pre-symptomatic (genetic carriers) and symptomatic (genetic and sporadic) indications</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zf5c4a6ec799844698daaa9cf8092921c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Pivotal study planned for 2021, design should provide a rapid path to market</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Akcea Integration Update</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The recently completed acquisition of Akcea has created a stronger, more efficient company, further bolstering Ionis&#8217; financial strength. The integration of Akcea is
        ahead of schedule, delivering cost synergies and efficiencies. It was also announced that Akcea is going to commercialize TEGSEDI and WAYLIVRA in Europe through a distribution agreement with Swedish Orphan Biovitrum AB (&#8220;Sobi&#8221;), an international
        biopharmaceutical company that focuses on rare diseases. Under the terms of this agreement, Akcea retains the marketing authorization (&#8220;MAH&#8221;) for both medicines in Europe. Additionally, Akcea will continue to maintain limited European operations
        including regulatory, manufacturing, and the management of relationships with key opinion leaders. Akcea will continue to lead the TEGSEDI and WAYLIVRA global commercial strategy. The agreement provides Ionis the flexibility to reinvest resources
        to support its other commercial plans.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Oral Delivery Development Update</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ionis and AstraZeneca are committed to bringing the best possible PCSK9 antisense treatments to patients and have been collaborating on both the subcutaneous and oral
        formulations. The subcutaneous formulation of ION449 has a potential best-in-class profile and is advancing rapidly toward Phase 3 development.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Preclinical and early clinical data give Ionis and AstraZeneca confidence that they can achieve effective oral delivery of ION449 and other ASOs.&#160; Based on ongoing
        research and experience to date, both companies believe they can improve upon the current oral formulation. Therefore, Ionis and AstraZeneca have decided to terminate the Phase 1 PCSK9 oral study. Ionis and AstraZeneca will continue to broadly work
        together to further optimize the oral delivery of ASOs, including ION449.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ionis is expanding its oral delivery to include medicines from its pipeline and has increased its internal investment in oral delivery research. The company plans on
        initiating one or more programs from its pipeline within the next year or two. Candidates for consideration include IONIS-TTR-L<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">Rx</sub>, IONIS-PKK-L<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">Rx</sub>, ION994 (AGT), and ION547. Success would further enhance the commercial value of
        Ionis-owned programs.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Webcast</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Additional details are available in the replay of the webcast. It is available <u><font style="font-size: 10pt; font-family: 'Times New Roman';">here</font></u> for a
        limited time.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Ionis Pharmaceuticals, Inc.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that
        can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved
        treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the
        patients we have yet to reach with a pipeline of more than 40 novel medicines designed to potentially treat a broad range of diseases, including neurological, cardio-renal, metabolic, infectious, and pulmonary diseases.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">To learn more about Ionis visit www.ionispharma.com or follow us on twitter @ionispharma.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Forward-looking Statements</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of SPINRAZA&#174; (nusinersen),
        TEGSEDI&#174; (inotersen), WAYLIVRA&#174; (volanesorsen) and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis&#8217; wholly owned subsidiary. Any statement describing Ionis&#8217; goals, expectations, financial
        or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on
        our business, and including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and
        effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis&#8217; forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to
        differ materially from those expressed or implied by such forward-looking statements. Although Ionis&#8217; forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known
        by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2019
        and our most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of this and other documents are available at www.ionispharma.com. In this presentation, unless the context requires otherwise, &#8220;Ionis,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221;
        and &#8220;us&#8221; refers to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals&#8482; is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics&#174; is a registered trademark of Akcea Therapeutics, Inc. TEGSEDI&#174; is a trademark of Akcea
        Therapeutics, Inc. WAYLIVRA&#174; is a registered trademark of Akcea Therapeutics, Inc. SPINRAZA&#174; is a registered trademark of Biogen.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis Pharmaceuticals Investor Contact:</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">D. Wade Walke, Ph.D.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Vice President, Investor Relations</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">760-603-2741</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis Pharmaceuticals Media Contact:</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Roslyn Patterson</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Vice President, Corporate Communications</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">760-603-2681</div>
      <div><br>
      </div>
      <div>&#160;
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ions-20201208.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://ionispharma.com/20201208" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ions="http://ionispharma.com/20201208" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20201208_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20201208_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://ionispharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ions-20201208_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ions-20201208_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://ionispharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ions-20201208.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ionispharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ": = # 2(  A$! Q$!_\0
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MW_OQ_P#7H_X7'X4_OWO_ 'X_^O7SU177[&)]7_8V&\_O/H7_ (7'X4_OWO\
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M1Y1X7\</^1ETW_KS_P#9VKRZO4?CA_R,NF_]>?\ [.U>75VT_A1]IEW^ZP]
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M5Z?\&=!O[G79-;2=H+&U#1.H)_TAF7[GI@9#'/?;QW'#^&O#]UXGUVWTRU#
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M>BYM4&%@NU\Q5&   <A@  , ''M6$Z/6)X.+R;FDYT';R_R/IBBO&+?XZSK
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M/:RO+_:OVM1>ZMO/_@'OG@_XL:9K:K:ZP8M.O\X#%L0R\9R&/W3P>&/I@DG
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M %_1?^A"G+8NO_"EZ,^J*R/$VOP^&?#]UJTT,DRP@;8T_B8G"@G^$9(Y_F<
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M[*#UVKVSZDX&<5G4GRKS/.S'&+#TFD_>>W^9T]%%%<9\>?'5%?6'_",Z!_T
M]-_\!(_\*/\ A&= _P"@'IO_ ("1_P"%=?M/(^N_M'^[^/\ P#Y/KU3X&_\
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MVFY .UA@Y1>B\C(/+#/WC78T45DVWN>35JSJRYIN["BBBD9A1110!X7\</\
MD9=-_P"O/_V=J\NKZYO-)TW4)%DO=/M+EU&U6FA5R!Z9(JM_PC.@?] /3?\
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1MMZL\2<Y3ES2=V%%%%(D_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>brhc10017778_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ions-20201208.xsd" xlink:type="simple"/>
    <context id="c20201208to20201208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2020-12-08</startDate>
            <endDate>2020-12-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20201208to20201208"
      id="Fact_e9b190f64daa4bd3a2cbdd79bb268c08">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20201208to20201208"
      id="Fact_305aa79557bf4bcc9e848cf8185df3b9">0000874015</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20201208to20201208"
      id="Fact_a7f96fdf1edf447c98a518c5ae53250f">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20201208to20201208"
      id="Fact_f6cac525beb94deaa225975cf5769101">2020-12-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20201208to20201208"
      id="Fact_207bac9ad4364357a0d1b8abb8a4e692">IONIS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20201208to20201208"
      id="Fact_4667772ae2e242a0bbca79d45cb90f4d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20201208to20201208"
      id="Fact_df9bdd1e42874b4d99bbb92356e4fece">000-19125</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20201208to20201208"
      id="Fact_1be3552bc8104f51a8ef2da949aefc70">33-0336973</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20201208to20201208"
      id="Fact_2e5646431e7f446fb8216bddce6d825a">2855 Gazelle Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20201208to20201208"
      id="Fact_ea743fda4de54a79b25f357bf3bd6e2a">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20201208to20201208"
      id="Fact_2d4c672aee474a3288cf04bf38d8785e">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20201208to20201208"
      id="Fact_d88d9b84bbc047ed89e862cd070ef3a8">92010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20201208to20201208"
      id="Fact_6c35838d472f43039b813e8e84d66740">760</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20201208to20201208"
      id="Fact_decde9ed4f254df68be3bf309e2fcca5">931-9200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20201208to20201208"
      id="Fact_fbb4a19851174eeb84218efc2398e9db">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20201208to20201208"
      id="Fact_99f2a24f1234474a95c9d6c2f4d4ea78">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20201208to20201208"
      id="Fact_d52bdedea7ed42b3bb096080bb127adc">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20201208to20201208"
      id="Fact_869c99fac6ee4e31a00572d792ade533">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20201208to20201208"
      id="Fact_bf46a798d2ac49fda3aafda61e189257">Common Stock, $.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20201208to20201208"
      id="Fact_8a6d249a77b0408cb0d83fe54671b9dd">&#x201c;IONS&#x201d;</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20201208to20201208"
      id="Fact_07257a0299a84cd2bbfb1bb30ec081b7">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20201208to20201208"
      id="Fact_f99dd419f2f444dbb89d066ffc3395be">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140430169156040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 08, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  08,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IONIS PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0336973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2855 Gazelle Court<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">931-9200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000874015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 Par Value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">&#8220;IONS&#8221;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M +\OE#)O%7L/+?^-,/X'4$L#!!0    ( +(QB5&#J:4#U $  #(&   -
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
M   ( +(QB5$<.&7J/P$  #P"   /    >&PO=V]R:V)O;VLN>&ULC5'+;L)
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " "R,8E1!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M +(QB5%&W&0_[@   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( +(QB5&97)PC$ 8  )PG   3
M  "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ LC&)4:Y_
MS\)'!   4A   !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( +(QB5&#J:4#U $  #(&   -
M  "  8H,  !X;"]S='EL97,N>&UL4$L! A0#%     @ LC&)49>*NQS
M$P(   L              ( !B0X  %]R96QS+RYR96QS4$L! A0#%     @
MLC&)41PX9>H_ 0  / (   \              ( !<@\  'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( +(QB5$D'INBK0   /@!   :              "
M =X0  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( +(Q
MB5%ED'F2&0$  ,\#   3              "  <,1  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(   T3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10017778_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionispharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="brhc10017778_8k.htm">brhc10017778_8k.htm</File>
    <File>brhc10017778_ex99-1.htm</File>
    <File>ions-20201208.xsd</File>
    <File>ions-20201208_lab.xml</File>
    <File>ions-20201208_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10017778_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "brhc10017778_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ions-20201208_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ions-20201208_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ions-20201208.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ions",
   "nsuri": "http://ionispharma.com/20201208",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10017778_8k.htm",
      "contextRef": "c20201208to20201208",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://ionispharma.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10017778_8k.htm",
      "contextRef": "c20201208to20201208",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001140361-20-027746-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-20-027746-xbrl.zip
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M)SS7L]?1]=W#>;#6A.HB <,[^K]P.&?A"\\3/O,(6/8&<:7P?.DY)A>&:\C
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M</>3;=#/__*=XXV/;OZPZYWU&G\T^NQ:JC.5RX(MX%J&UPO&XX44UP*II!@
M&BR70L>29S 2#20SWS"> W6)>)$#'N#7Y)KGL7F \9*=Y=>B*)5FIWSSH3,M
M>004%XLL*U8\!C)\=C ^H.\KGB3U=YD\._@]\4+728+8<?C8G7E>X,]"$4;3
MT)TD[B0-X+&,%\6S@]/+\U>O95&^0]B?3G.TJ_AE_/T'$Z#YU^$<,$/]O/L=
MKR3UF.I7!"O"I>C&K4_*Y,.>9M="ES+F63W(4JV.6(]^/AIM#IX//V@ AJ)W
M#F 'Q?2A]9']TQ";'CYDLH07Q?"&<RV5EJ7\'3D\XNQ*BQ77^$T"I@(S6^-G
M(H"A6N<@#59R)4 (" "H.Z@O?^>E5'D?9V_9&KB@=^  7$8T[)-"=Z<_G2"B
M,([2V2P%W'?<Z706N$$037D\B3QG&H;3/4'L"<(0A"J!1R,K+Q7+>)7'"^;]
M%\L!T$JKI(J!*F0.W]^7+)77@FT$U\4]Q?HD#$0T#GC( Q #+@_C\209!U,_
M\(-@$OA[K-]CO<7Z0B+W!O:.7)VC'J. [X.:YI!8B,1&Y<G71/,_TB4_85]N
MJL,W%N5?P=M2"D^.+UY?OC@^'; 3&%LZ&K!3$8]8,""+QVK4["_?!1/'.6+'
M)0G4KMX'K*, '37AFX$1L.VBG2^X7O)85(0?H&*>Y0#ZT9OCR]/COQZRL[=O
M+A^W^B@:<@N!LGC%\PV]T3\J6 $+)E,  !/O*JS(O\@HPXU558G"/*'1-=HK
M\#ZP_4"F"X)<5%%1<L,6U6JE=%GELMPPE=)CM48P^I,Z^R?O+6<Y7P*PW__W
MI^QJ%DS'01 Z:$+P6G7G!:"PR#OJC5%V.MI/5]]9+U26P?P^0.'!U:1?U[)<
M$) =YL"(O5N(=GNW=ZKS1#TDF#37N/I:B&$*&'?('CF/ 0\D[@*,+04KO:C'
MW0$@4A@F7(*1:820R$+P L#A^&"LM&%:98@9(,8J;0T46(Z8ZT2:KZD&<V4A
M\;E'D\>P!, ;A"8Q"";JE0 @ZX6@ >)??%&N&+_F,B/Q5*+KP&#;H^ECZTG
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M!ON^5%KTUP/P5U7S!8H*;V"XFP Q E2) &%1D@UAC(6#RP?JI"J0$\+"K ?
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M#-Z(_$9]B38])PJJMVO 3^3WR$X+POW_=&8,M(K,R&'4Q7G/OX/O0DY,JC:
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M KZ]PG?-V2E\&:Y%4_';QDM@&FL,!M=I19W0RUV56S\'P58?\R(I0$66FTN
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M>+MHLMS5)$?%S/QN=0^7!Y6ALG]L/:+TES^^GD)V)\U=%$O6JS]02P,$%
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MRH] B8WDX?)\:< 4)V1-?:STH(W@2S2/]IHJ::7SH9E,5Q'KEE\<X'CX^6&
MPL"DG65-Z!_1^._;T6[4^I&>4WEU/.J+(;&/%8=1*$8^85OF<SJ4CFA!R<JT
M#J1B^HK9R/Q.D21#*4&&W%%+W%W&;'ROYT' R$B*OUCQX+%"2*6N.$R+K@&;
M1E=7G%9U8&+6GC?+PZ@(O!$?$)>@VQAWRW/UFI(]IE_FW)@BF*_P[)K_24W^
M)S7YGQR$_\FA^9]\(_^3&OP_OI!^\C^IR_]D?_XG5?Q/^L'_M";_TYK\3P_"
M__30_$^_D?]I'?[9LO5T!YC6K8#I_A4PK:J :;L5<+YB-P;L=_HA\I8*>V"L
M.$PEUH!NR<D5T9"IB6)=.]LV(=[6+:7P*I"*R9-IE&2"0""W+>HN./H4>Q<D
M4)& 0N)N3PHUN=DK&3F[U],]C;=ZJG1VD9TG61/B;1W?YT$+0.P3I]SEE53;
MFSPMLY,]G@_CECZ2E]BVP^LJ:'\OJUSM[CO/@^SMFGVMG5W)TO;UC%Y"$5?T
M:$<'5A':S^$IM^SFNP1P+U?]NN&<K..4OEHAER4@X4+B#._<\#!L2][UP"ZE
MZ%3GP3X!K:P82+,^PS:4<S7,<=FI+8C?$W_-+TFV7R>\]U*5*JNF.%B#I@''
MH*,KD&WF)I+-.3,10GF,K7F >+1;ENWK1FI.LTPS*!<X6[S:/2E?Q3ZASX1F
MW[D_I&P417$!U[][9$BG[(J,QF=PJ[_;$WJ=KNSG]VH'<;J7E&]0IN77,N+,
MV/WU^#Y D&]:,6B#L";+^T6-?MHJ-_Y>2W3W1&)\LU[-,55H-H6+"=###:I&
M-7-5(@9?4SV \EG6BK)FE+=WR[AQ84CU9,KTJDJ!*NS0R;7Y'4E2+_H[?#:>
M_6U"Z#I=$;JZ6I=L#W+-#O50Z\I=3]2NWW,)8IK>G,2MZPI=S1M7P')-+^6
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M8)3#)0'(W16&9GZ@\C#U4[-(X'2]5')=?RO&O/1PW5B7QUH]6J:AA@P]M/L
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M,# Q-S<W.%\X:RYH=&U02P$"% ,4    " "R,8E1W_S6E'L;   GD@  %P
M            @ %H$@  8G)H8S$P,#$W-S<X7V5X.3DM,2YH=&U02P$"% ,4
M    " "R,8E1>>;R]7$#  "-$   $0              @ $8+@  :6]N<RTR
M,#(P,3(P."YX<V102P$"% ,4    " "R,8E1NZ)M_YX(   @60  %0
M        @ &X,0  :6]N<RTR,#(P,3(P.%]L86(N>&UL4$L! A0#%     @
MLC&)48ZC9Y_N!0  HS\  !4              ( !B3H  &EO;G,M,C R,#$R
@,#A?<')E+GAM;%!+!08     !0 % $L!  "J0      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
